How do you make Pharmacy First actually pay?

Where does the service stand?

Pharmacy First is no longer a new service. Between April 2025 and January 2026, community pharmacies delivered over 2.75 million clinical pathways consultations. Alongside those came nearly one million contraception service consultations and three million hypertension case-finding consultations. That places the service firmly among the established elements of the contractual framework, not among its experiments.

Two structural changes for 2026/27 confirm that position. The Pharmacy First budget previously funded the clinical pathways consultations, the Pharmacy Contraception Service and the Hypertension Case-Finding Service separately. It has now been fully merged into the core contractual sum, which guarantees the funding envelope to the sector. And independent prescribing arrives as an extension of Pharmacy First and the Contraception Service from autumn 2026 — the most substantial expansion of the service since it began.

What has not settled is whether an individual pharmacy earns from it. The service pays through a modest item fee, fixed payments awarded at activity thresholds, and monthly caps beyond which further activity attracts no fee. That combination produces outcomes which surprise operators who model it as a simple fee per consultation. Two pharmacies delivering similar volumes may receive materially different sums. The difference is frequently decided during the final week of a month.

How does payment actually work?

The item fee of £17 for clinical pathways consultations remains unchanged under the 2026/27 arrangements. Prescribing consultations within existing pathways are paid at the same rate as their PGD equivalents. The fixed payment arrangements are likewise maintained, and independent prescribing clinical pathway consultations count toward the same thresholds.

Why are the thresholds cliffs?

The history behind those thresholds explains why they attract resentment as well as attention. The minimum activity requirement escalated substantially after launch, rising from five consultations per month during 2024 to thirty by March 2025. That trajectory was raised in Parliament in February 2026. A member described a constituent pharmacy which never met the threshold and was therefore, in his characterisation, delivering the service for nothing.

That criticism is fair as far as it goes, and it identifies a genuine distributional effect. A threshold system concentrates payment on pharmacies able to reach it and pays nothing extra to those which cannot. But the same structure rewards a pharmacy that organises deliberately around the thresholds. It pays considerably more than the same total activity delivered without regard to when it falls.

What do the caps do?

At the opposite end of the distribution sits the cap. Each pharmacy is assigned to a band carrying a monthly maximum number of clinical pathways consultations which attract the item of service fee. Band assignments and caps are published each month by the NHSBSA. Activity above the cap attracts no fee.

For 2026/27 the cap arrangements are maintained. An additional allowance is made to each capping band for contractors delivering independent prescribing consultations. That produces two caps within each band: one for pharmacies signed up for prescribing services, one for those which are not. Separately, the Government has indicated it intends to implement high-level caps for the hypertension case-finding service and the Pharmacy First minor illness service, to restrict the highest-volume outliers. Details are to be agreed during the year.

The practical implication: Pharmacy First rewards activity within a range, not without limit. A pharmacy substantially below its cap gains from each additional consultation. One at its cap gains nothing further within the month. It would be better served directing capacity toward services which are not capped — other commissioned services, or the private work examined in the revenue playbook. Knowing which position applies means reading the published band and cap rather than assuming. The figures are republished monthly for that reason.

What are the gateway requirements?

Payment under the fixed arrangements is not available merely for delivering clinical pathways consultations. The contractor must be registered for, and able to deliver, the Hypertension Case-Finding Service and the Pharmacy Contraception Service alongside Pharmacy First. The minimum activity requirement for the clinical pathways themselves applies on top.

Those requirements have accumulated. A minimum of one ambulatory blood pressure monitoring per month was added from October 2025, and a minimum number of contraception consultations was introduced from March 2026. The effect: the fixed payment rewards a portfolio of services, not one. A pharmacy delivering excellent Pharmacy First activity while neglecting ambulatory monitoring may forfeit the fixed payment entirely, whatever its clinical pathways volume.

For an owner reviewing whether the service pays, check that structure before anything else. The most expensive failure available is delivering thirty consultations and receiving no fixed payment because a single ambulatory blood pressure monitoring was not completed.

What does independent prescribing change?

From autumn 2026, independent prescribing enters the contractual framework as an extension of Pharmacy First and the Contraception Service. Community pharmacist prescribers will be able to prescribe within the existing Pharmacy First clinical pathways and the Contraception Service without a Patient Group Direction. They will also be able to provide up to five new prescribing-only Pharmacy First pathways.

The conditions under consideration for those new pathways have been reported as bacterial conjunctivitis, allergic conjunctivitis, oral thrush, skin infections and respiratory tract infections. They are not yet settled. The pathways require approval by a clinical reference group NHS England is establishing — mainly pharmacists and general practitioners, with input from other bodies including NICE.

Until the arrangements commence, the position is unchanged: all pharmacists providing the service must continue to use the PGDs and the clinical protocol. The prescribing route also depends on the Electronic Prescription Service. That is an infrastructure requirement rather than a clinical one — confirm it rather than assume it.

The clinical case is straightforward. Prescribing within a consultation removes the ceiling a PGD imposes on what may be supplied. It permits an alternative item where an individual patient's needs require one, and reduces the referrals back to general practice a PGD-limited consultation generates. Evidence cited during the parliamentary exchange referred to a pathfinder pharmacy where only five per cent of patients seen by prescribers went on to require GP prescribing.

Does the prescribing arithmetic work?

The commercial case deserves a more sceptical look than the clinical one. The sector's own commentary has given it exactly that.

The funding is a one-off set-up fee of £500 and a monthly infrastructure payment of £525. Consultation fees do not rise: prescribing consultations within existing pathways are paid at the same rate as PGD consultations. The fixed payment thresholds are likewise maintained, with prescribing consultations counting toward the same 20 and 30 consultation bands rather than toward higher ones. Commentary published after the settlement identified the consequence directly. A pharmacy already reaching those thresholds through ordinary Pharmacy First activity gains no additional fixed payment from prescribing. That raises a genuine question about where the incentive sits for such a pharmacy.

The counter-argument is the capping allowance. Contractors delivering prescribing consultations receive an additional allowance within each band. That benefits precisely the pharmacies operating near their cap, and it is where the incremental revenue actually resides. A pharmacy well below its cap gains little from prescribing beyond the infrastructure payment. A pharmacy at its cap gains headroom it could not otherwise obtain.

Funding is not the only constraint. The Pharmacists' Defence Association identified workforce capacity, the suitability of pharmacy premises and safe staffing models as matters requiring attention if the expansion is to succeed. It is a reminder that a prescribing consultation occupies a qualified prescriber and a consultation room for a period the £17 fee does not obviously purchase.

The honest summary: the prescribing extension improves the service clinically and improves its economics selectively. It benefits capped high-volume pharmacies, and those able to reach thresholds only with the additional pathways. It offers less to pharmacies whose constraint is demand rather than capacity.

What makes the service pay?

Five operational arrangements separate pharmacies for which Pharmacy First contributes from those for which it merely occupies.

Know the month-to-date figure weekly. The twentieth and thirtieth consultations each carry about £500, so the count is a pricing input rather than a report. It must be visible early enough in the month to be acted on.

Know the band and the cap. The published figures determine whether additional activity earns or does not, and they are republished monthly. A pharmacy operating at its cap should redirect capacity rather than continue.

Protect the gateway services. The ambulatory monitoring and contraception minima are small quantities of activity guarding a payment of up to £1,000. That makes them the highest-return tasks in the month, and the ones most easily forgotten.

Convert referrals rather than awaiting them. The pathways depend on patients presenting. A pharmacy relying wholly on referral routes will fluctuate around the thresholds rather than clearing them. The counter conversation, the visible offer and the local practice relationship are what convert an eligible presentation into a consultation.

Record and claim correctly. A consultation delivered and not claimed pays nothing. That failure is more common than it should be in a service whose claim requirements have changed repeatedly.

What has changed about claims?

The claim window tightened during 2025/26. It was reduced to one month to enable the variable payment arrangements. That placed Pharmacy First among the small number of Advanced services operating a single-month window, and made late claiming fatal rather than merely inconvenient.

Community Pharmacy England has since secured agreement that a later claim period will be re-introduced. A two-month late claim window is to be introduced during 2026, giving pharmacy owners three months in total to claim. That is a material easing for pharmacies whose month-end processes have occasionally lost consultations. Confirm the implementation date rather than assuming the extended window is already available.

Two adjacent changes complete the position for 2026/27. New Medicine Service contractor caps have been adjusted down to 0.9 per cent of monthly prescriptions, reflected in the Drug Tariff for activity from June 2026. And the Pharmacy Quality Scheme continues with a reduced budget of £20 million and fewer requirements. No clinical audits are required, and the aspiration payment rises from 75 to 80 per cent, payable on 1 September.

Key takeaways

FAQs